Maxacalcitol

Maxacalcitol

Clinical data
Trade names	Oxarol
Other names	22-Oxacalcitriol; OCT
Routes of administration	IV or topical
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
IUPAC name (1R,3S,5Z)-5-[(2E)-2-[(1S,3aS,7aS)-1-[(1S)-1-(3-Hydroxy-3-methylbutoxy)ethyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
CAS Number	103909-75-7
PubChem CID	6398761
IUPHAR/BPS	2784
DrugBank	DB06272
ChemSpider	4911262
UNII	N2UJM5NBF6
ChEBI	CHEBI:31801
ChEMBL	ChEMBL333950
CompTox Dashboard (EPA)	DTXSID4048648
ECHA InfoCard	100.212.050
Chemical and physical data
Formula	C26H42O4
Molar mass	418.618 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@@H]([C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C)OCCC(C)(C)O
InChI InChI=1S/C26H42O4/c1-17-20(15-21(27)16-24(17)28)9-8-19-7-6-12-26(5)22(10-11-23(19)26)18(2)30-14-13-25(3,4)29/h8-9,18,21-24,27-29H,1,6-7,10-16H2,2-5H3/b19-8+,20-9-/t18-,21+,22+,23-,24-,26+/m0/s1 Key:DTXXSJZBSTYZKE-ZDQKKZTESA-N

Maxacalcitol (trade name Oxarol) is a vitamin D₃ analog and vitamin D receptor activator (VDRA). ^[1] As a pharmaceutical drug, it is used as an injection to treat secondary hyperparathyroidism resulting from hemodialysis and as a topical ointment for psoriasis. ^[2]

It was approved for use in Japan in 2010 ^[3] and in Taiwan in 2018. ^[4]

References

1. Mizobuchi M, Ogata H (March 2014). "Clinical uses of 22-oxacalcitriol". Current Vascular Pharmacology. 12 (2): 324–328. doi:10.2174/15701611113119990023. PMID   23713875.
2. "Maxacalcitol". Inxight Drugs. National Center for Advancing Translational Sciences, U.S. National Institutes of Health.
3. "Maxacalcitol". New Drug Approvals in Japan. Kyoto Encyclopedia of Genes and Genomes. D01098.
4. Fukazawa-Shinotsuka M, Saito T, Abe M, Iida S, Wang IT, Terao K, et al. (January 2022). "Maxacalcitol Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Secondary Hyperparathyroidism in Patients Receiving Maintenance Hemodialysis". Drug Research. 72 (1): 23–33. doi:10.1055/a-1581-7609. PMID   34488237.